Currently, Black Diamond Therapeutics Inc [BDTX] is trading at $4.09, down -5.32%. An important factor to consider is whether the stock is rising or falling in short-term value. The BDTX shares have gain 5.14% over the last week, with a monthly amount glided 21.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Black Diamond Therapeutics Inc [NASDAQ: BDTX] stock has seen the most recent analyst activity on September 04, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $8. On July 31, 2024, Raymond James initiated with a Outperform rating and assigned a price target of $20 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating. Stifel upgraded its rating to a Buy and raised its price target to $10 on June 30, 2023. H.C. Wainwright upgraded its rating to Buy for this stock on June 28, 2023, but kept the price target unchanged to $11. In a note dated June 27, 2023, Wedbush upgraded an Outperform rating on this stock but restated the target price of $10.
This stock has fluctuated between a low of $1.20 and a high of $4.35 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $4.09 at the most recent close of the market. An investor can expect a potential return of 95.6% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.07%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.13 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Black Diamond Therapeutics Inc [NASDAQ:BDTX] is 8.73. On the other hand, the Quick Ratio is 8.73, and the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 3.33, the price to book ratio is 1.75 and price to earnings (TTM) ratio is 17.27.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Mar 19 ’25 when 5.78 million shares were sold.
